A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA

• https://x.com/i/web/status/1858510483290247578
• https://x.com/synovialjoints/status/1858510483290247578/photo/1

If a mother has had TNFi during pregnancy, can a baby have a live oral rotavirus vaccine (usually at 2mo)? This claims data suggests no increase in diarrhoea Adds to similarly reassuring 🇨🇦prospective cohort data https://t.co/2Tz9zRhPjz Vaccinate away! #ACR24 ABST0806 @RheumNow https://t.co/66OIAR8W6l

• Immunological effects and safety of live rotavirus vaccination after antenatal …
• https://x.com/drdavidliew/status/1858509769163902986/photo/1

Instead of just JAKi, why don't we look at all our RA meds and MACE risk FAERS data & reporting odds ratios here: all the caveats of voluntary reporting, so don't put too much weight, but... prednisone. Don't forget pred is really not great for MACE! #ACR24 ABST1981 @RheumNow https://t.co/L9SlPZF2Jd

• https://x.com/drdavidliew/status/1858471335137276261/photo/1

Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow https://t.co/w58MNqRt1T

• https://x.com/drdavidliew/status/1858475993591157006/photo/1

Effective RA therapy is about more than just joints 🇪🇸 RA cohort TNFi for first 24w led to: Lean mass index i.e. muscle going up Fat mass index i.e. fat trending down Muscle & fat composition are important Systemic Rx can deliver systemic benefits #ACR24 ABST1348 @RheumNow https://t.co/mZjcHwxMgW

• https://x.com/drdavidliew/status/1858482788514873607/photo/1

Steroids in checkpoint inhibitor rheumatic irAEs need to be approached with caution. Persistent higher doses earlier on might dampen ICI response. @HSpecialSurgery ICI-IA (inflamm arthritis) cohort big diff in survival based on early steroid exposure #ACR24 ABST1989 @RheumNow https://t.co/3WAZ3ZLbFw

• https://x.com/drdavidliew/status/1858483970268401794/photo/1

Here's a meta-analysis of MACE/malignancy in JAKi vs TNFi in observational cohort studies. All the epidemiological challenges here aside, it's a good reminder that with ORAL Surveillance it's *cardiovascular risk enriched pts* we're concerned about. #ACR24 ABST2264 @RheumNow https://t.co/vIXlrI3V2d

• https://x.com/drdavidliew/status/1858489054561816946/photo/1

RA patients on TOF with h/o ASCVD have 4x higher risk of MACE without statin (vs. TNFi). Prioritize statins for heart health in RA! #ACR24 @RheumNow ABST#1745 https://t.co/jRqXNU2T6d

• https://x.com/JihaRheum/status/1858252521044893744/photo/1
• https://x.com/JihaRheum/status/1858252521044893744/photo/1

The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al. axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed @RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x

• https://x.com/RHEUMarampa/status/1858252752427626764/photo/1

A#1745 Post-hoc ORAL Surveillance - statin <1/4 on a statin, only 53% h/o ASCVD on statin Incr in LDL was less on Tofa pts on statin Among those on b/l statins, there is no incr risk compare to TNFi, esp pts h/o ASCVD If high risk on tofa, statin helps! @RheumNow #ACR24 #ACRBest https://t.co/7MGgUk7tfI

• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1

In a cohort of >17,000 European pts w/ axSpA: -bDMARD naïve pts starting TNFi or IL-17Ai were more likely to achieve LDA than TNF-experienced. -Higher time to achieve LDA and shorter durability in pts with prior TNFi use. Abst#1756 #ACR24 @RheumNow

Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3

• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1